Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Peder L. Myhre, Muthiah Vaduganathan, Brian Claggett, Zi Michael Miao, Pardeep S. Jhund, Rudolf A. de Boer, Adrian F. Hernandez, Silvio E. Inzucchi, Mikhail Kosiborod, Carolyn S.P. Lam, Felipe A. Martínez, Sanjiv J. Shah, Akshay S. Desai, Daniel Lindholm, Magnus Petersson, Anna Maria Langkilde, John J.V. McMurray, Scott D. Solomon
Topics & Concepts
MedicineHeart failureEjection fractionInternal medicineCardiologyDapagliflozinNatriuretic peptideHeart failure with preserved ejection fractionAtrial fibrillationPlaceboQuartileEndocrinologyDiabetes mellitusConfidence intervalAlternative medicineType 2 diabetesPathologyHeart Failure Treatment and ManagementDiabetes Treatment and ManagementCardiovascular Function and Risk Factors